Dr. Madakamutil brings over 20 years of experience in developing transformative therapies that harness the immune system, having served in senior research and development positions in global biopharmaceutical companies including Nektar Therapeutics, Janssen, Takeda and Celgene.
Before joining ImCheck, Dr. Madakamutil was the Chief Scientific Officer and co-founder at Invivoscribe Therapeutics where he pioneered the development of a small molecule precision oncology program for the treatment of acute myeloid leukemia. Prior to this, he held the position as Senior Vice President and Head of Discovery and Preclinical Development at Nektar Therapeutics where he was responsible for the discovery strategy and for bringing novel immune-modulatory medicines for the treatment of cancer and autoimmune diseases toward clinical evaluation. He also served in several senior leadership positions in R&D and preclinical development at Janssen Inc., Takeda and Celgene. Through these positions, Dr. Madakamutil has built a significant network in the US and globally.
He did his Post-Doctoral training at the La Jolla Institute for Allergy and Immunology and graduated from the University of Mumbai, India, with a PhD in Immunology.